Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRAFT: AzaFol-PET/CT in the Diagnosis of Giant Cell Arteritis
NCT06335888Phase 2Recruiting
- Sponsor
- Insel Gruppe
- Start
- Feb 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of [18F]-AzaFol in giant cell arteritis (GCA) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Specificity of the GCA-diagnosis at the patient level. Started Feb 2025; status: recruiting.
02
Drugs
[18F]-AzaFol
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT06335888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335888.